- Home
- TSI vs LUNG Comparison
TSI vs LUNG Comparison
Compare TSI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- LUNG
- Stock Information
- Founded
- TSI 1987
- LUNG 1995
- Country
- TSI United States
- LUNG United States
- Employees
- TSI N/A
- LUNG N/A
- Industry
- TSI Investment Managers
- LUNG Industrial Specialties
- Sector
- TSI Finance
- LUNG Health Care
- Exchange
- TSI Nasdaq
- LUNG Nasdaq
- Market Cap
- TSI 241.8M
- LUNG 251.5M
- IPO Year
- TSI N/A
- LUNG 2020
- Fundamental
- Price
- TSI $5.05
- LUNG $6.06
- Analyst Decision
- TSI
- LUNG Buy
- Analyst Count
- TSI 0
- LUNG 6
- Target Price
- TSI N/A
- LUNG $11.92
- AVG Volume (30 Days)
- TSI 106.8K
- LUNG 214.8K
- Earning Date
- TSI 01-01-0001
- LUNG 10-30-2024
- Dividend Yield
- TSI 7.46%
- LUNG N/A
- EPS Growth
- TSI N/A
- LUNG N/A
- EPS
- TSI N/A
- LUNG N/A
- Revenue
- TSI N/A
- LUNG $79,302,000.00
- Revenue This Year
- TSI N/A
- LUNG $22.26
- Revenue Next Year
- TSI N/A
- LUNG $18.72
- P/E Ratio
- TSI N/A
- LUNG N/A
- Revenue Growth
- TSI N/A
- LUNG 22.34
- 52 Week Low
- TSI $4.48
- LUNG $5.46
- 52 Week High
- TSI $4.87
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- TSI 56.00
- LUNG 44.10
- Support Level
- TSI $5.01
- LUNG $6.07
- Resistance Level
- TSI $5.07
- LUNG $6.32
- Average True Range (ATR)
- TSI 0.03
- LUNG 0.39
- MACD
- TSI 0.00
- LUNG -0.02
- Stochastic Oscillator
- TSI 67.86
- LUNG 21.03
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.